Crinetics Pharmaceuticals, Inc. (CRNX)
NASDAQ: CRNX · Real-Time Price · USD
36.79
+0.01 (0.03%)
At close: May 27, 2026, 4:00 PM EDT
36.79
0.00 (0.00%)
After-hours: May 27, 2026, 4:57 PM EDT
Crinetics Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 16 analysts polled by S&P Global, Crinetics Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $83.14. The average 1-year stock price forecast is 125.99% higher than the current stock price, while the lowest is $55 (+49.50%) and the highest is $97 (+163.66%).
Price Target: $83.14 (+125.99%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Crinetics Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 12 | 12 | 12 | 12 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Buy Reiterates $89 → $88 | Buy | Reiterates | $89 → $88 | +139.20% | May 15, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $87 → $84 | Buy | Maintains | $87 → $84 | +128.32% | May 11, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $97 | Buy | Maintains | $97 | +163.66% | May 8, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $83 | Buy | Maintains | $83 | +125.60% | May 8, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $81 | Buy | Reiterates | $81 | +120.17% | May 8, 2026 |
Financial Forecast
Revenue This Year
69.94M
from 7.70M
Increased by 808.74%
Revenue Next Year
181.91M
from 69.94M
Increased by 160.11%
EPS This Year
-5.04
from -4.95
EPS Next Year
-4.33
from -5.04
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 79.9M | 226.7M | ||||||
| Avg | 69.9M | 181.9M | ||||||
| Low | 56.6M | 130.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 938.0% | 224.1% | ||||||
| Avg | 808.7% | 160.1% | ||||||
| Low | 635.2% | 87.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -4.35 | -3.55 | ||||||
| Avg | -5.04 | -4.33 | ||||||
| Low | -5.81 | -5.02 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.